Treatment slows onset of Alzheimer’s
Israel’s Avraham Pharmaceuticals announced successful interim results in a Phase 2b clinical trial of ladostigil, for the treatment of mild cognitive impairment (MCI). Fewer MCI patients using ladostigil for 2 years progressed to Alzheimer’s than those using the placebo.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink